Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. Summary
    ADXN   CH0029850754

ADDEX THERAPEUTICS LTD

(ADXN)
  Report
Delayed Swiss Exchange  -  03:00 2022-09-30 am EDT
0.1398 CHF   -0.14%
09/20Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
GL
09/20Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
AQ
09/14Addex Therapeutics : INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K/A
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/26/2022 09/27/2022 09/28/2022 09/29/2022 09/30/2022 Date
0.135(c) 0.138(c) 0.1398(c) 0.14(c) 0.1398 Last
129 132 41 285 168 486 34 905 1 000 Volume
-8.04% +2.22% +1.30% +0.14% -0.14% Change
More quotes
Estimated financial data (e)
Sales 2022 0,91 M 0,92 M 0,92 M
Net income 2022 -21,3 M -21,8 M -21,8 M
Net cash position 2022 3,26 M 3,33 M 3,33 M
P/E ratio 2022 -0,33x
Yield 2022 -
Sales 2023 0,54 M 0,55 M 0,55 M
Net income 2023 -9,60 M -9,80 M -9,80 M
Net cash position 2023 6,01 M 6,13 M 6,13 M
P/E ratio 2023 -0,82x
Yield 2023 -
Capitalization 6,89 M 7,03 M 7,03 M
EV / Sales 2022 4,01x
EV / Sales 2023 1,63x
Nbr of Employees 26
Free-Float 48,9%
More Financials
Company
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced... 
More about the company
Ratings of Addex Therapeutics Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about ADDEX THERAPEUTICS LTD
09/20Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader I..
GL
09/20Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader I..
AQ
09/14Addex Therapeutics : INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENT..
PU
08/18Transcript : Addex Therapeutics Ltd, Q2 2022 Earnings Call, Aug 18, 2022
CI
08/18Addex Therapeutics : INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENT..
PU
08/18Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporat..
GL
08/18Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporat..
DJ
08/15Addex Therapeutics : and Indivior Extend GABAB Positive Allosteric Modulator Research Coll..
PU
08/15Addex Therapeutics, Indivior PLC Extend Collaboration Deal, Adds Research Funding
MT
08/15Addex, Indivior to Include Chronic Cough Indication in Research Collaboration
MT
08/15Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration fo..
GL
08/15Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration fo..
DJ
08/15Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration fo..
CI
08/12Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call ..
GL
08/12Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call ..
AQ
More news
News in other languages on ADDEX THERAPEUTICS LTD
08/18Bourse Zurich: le SMI tente de se rapprocher des 11'200 points
08/18Addex weitet Verlust im Q2 weiter aus - Finanziert bis Q1 2023
08/18Addex se voit désormais financé jusqu'au 2e trimestre 2023
08/15Addex Therapeutics et Indivior PLC prolongent leur accord de collaboration et ajoutent ..
08/15Addex et Indivior vont inclure l'indication de la toux chronique dans leur collaboratio..
More news
Analyst Recommendations on ADDEX THERAPEUTICS LTD
More recommendations
Chart ADDEX THERAPEUTICS LTD
Duration : Period :
Addex Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADDEX THERAPEUTICS LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 0,14 CHF
Average target price 0,16 CHF
Spread / Average Target 14,3%
EPS Revisions
Managers and Directors
Timothy Dyer Chief Executive Officer & Director
Lénaic Teyssédou Head-Finance
Vincent M. Lawton Chairman
Roger G. Mills Director & Chief Medical Officer
Jake R. Nunn Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ADDEX THERAPEUTICS LTD-86.54%7
MODERNA, INC.-53.51%46 189
LONZA GROUP AG-38.51%35 456
IQVIA HOLDINGS INC.-35.63%33 872
ALNYLAM PHARMACEUTICALS, INC.24.28%25 132
SEAGEN INC.-12.23%25 028